Skip to main content
SpringerLink
Log in

Vorgehen in Prä- und Postmenopause

Adjuvante endokrine Therapie des Mammakarzinoms

  • zertifizierte fortbildung
  • Published:
Info Onkologie Aims and scope

Zusammenfassung

Bei Brustkrebspatientinnen mit Östrogen- und/oder Progesteronrezeptor-positiven Tumoren ist eine adjuvante endokrine Therapie indiziert. Neben Risikoprofil und Nebenwirkungen sollte für die Therapie der Menopausestatus der Betroffenen Beachtung finden.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

Literatur

  1. www.awmf.org/leitlinien/detail/ll/032-045OL.html

  2. www.ago-online.de/de/infothek-fuer-aerzte/leitlinienempfehlungen/mamma/

  3. Hammond ME et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–95.

    Article  PubMed  PubMed Central  Google Scholar 

  4. www.nccn.org/professionals/physician_gls/pdf/breast.pdf

  5. Ravdin RG et al. Results of a clinical trial concerning the worth of prophylactic oophorectomy for breast carcinoma. Surg Gynecol Obstet. 1970;131(6):1055–64.

    CAS  PubMed  Google Scholar 

  6. Early Breast Cancer Trialists’ Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet. 1996;348(9036):1189–96.

    Article  Google Scholar 

  7. Goldhirsch A et al. Personalizing the treatment of women with early breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Partridge AH et al. First international consensus guidelines for breast cancer in young women (BCY1). Breast. 2014;23(3):209–20.

    Article  PubMed  Google Scholar 

  9. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–84.

    Article  Google Scholar 

  10. Braems G et al. Use of tamoxifen before and during pregnancy. Oncologist. 2011;16(11):1547–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Clemons M, Simmons C: Identifying menopause in breast cancer patients: considerations and implications. Breast Cancer Res Treat. 2007;104(2):115–20.

    Article  CAS  PubMed  Google Scholar 

  12. Tevaarwerk AJ et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2014;32(35):3948–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Francis PA et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372(5):436–46.

    Article  PubMed  Google Scholar 

  14. Pagani O et al. Adjuvant exemestan with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371(2):107–18.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Gnant M et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol. 2015; 26(2):313–20.

    Article  CAS  PubMed  Google Scholar 

  16. Ribi K et al. Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol. 2016;34(14):1601–10.

    Article  PubMed  Google Scholar 

  17. Kim HA et al. The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress. BMC Cancer. 2016;16:319.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Regan MM et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials. J Clin Oncol. 2016;34(19):2221–31.

    Article  PubMed  Google Scholar 

  19. Coates AS et al. Tailoring therapies Ȕ improving the management of early breast cancer: St Gallen International Expert Consensus on the primary therapy of early breast cancer 2015. Ann Oncol. 2015;26(8):1533–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Burstein HJ et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression. J Clin Oncol. 2016;34(14):1689–701.

    Article  PubMed  Google Scholar 

  21. Harbeck N, Herausgeber. Zielgerichtete Therapien beim Mammakarzinom. Der Praxisguide. 1. Auflage. Stuttgart: Schattauer Verlag; 2014.

    Google Scholar 

  22. Ryden L et al. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials. Breast. 2016;26:106–14.

    Article  PubMed  Google Scholar 

  23. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–52.

    Article  Google Scholar 

  24. O`Leary CG et al. Extended adjuvant endocrine therapy in hormone receptor-positive early breast cancer. Curr Opin Oncol. 2016;28(6):455–460.

    Article  CAS  Google Scholar 

  25. Gray RG et al. ATTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. 2013; 31(Suppl):Abstr 5.

    Google Scholar 

  26. Davies C et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomized trial. Lancet. 2013;381(9869):805–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Goss PE et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262–71.

    Article  CAS  PubMed  Google Scholar 

  28. Mamounas EP et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol. 2008;26(12):1965–71.

    Article  CAS  PubMed  Google Scholar 

  29. Jakesz R et al. Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG 6a). J Clin Oncol. 2005;23(16 Suppl):Abstr 527.

    Google Scholar 

  30. Zdenkowski N et al. Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomized, controlled trial. Ann Oncol. 2016;27(5):806–12.

    Article  CAS  PubMed  Google Scholar 

  31. Goss PE et al. A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. J Clin Oncol 2016; 34(Suppl):Abstr LBA1.

    Google Scholar 

  32. Barroso-Sousa R, Metzger-Filho O. Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications. Ther Adv Med Oncol. 2016;8(4):261–6.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Burstein HJ et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255–69.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Bauerschlag DO et al. Standard of care and controversies in the adjuvant endocrine treatment of hormone-responsive early breast cancer. Breast Care (Basel). 2014;9(4):283–6.

    Article  Google Scholar 

  35. Harris LN et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016;34(10):1134–50.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Spring LM et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(11):1477–1486.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitäts-Frauenklinik am Klinikum Südstadt Rostock, Südring 81, 18059, Rostock, Deutschland

    Steffi Hartmann,  Toralf Reimer & Angrit Stachs

Authors
  1. Steffi Hartmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toralf Reimer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Angrit Stachs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toralf Reimer.

Additional information

Interessenkonflikt

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrags von keinen wirtschaftlichen Interessen leiten ließen. Die Autoren legen folgende potenzielle Interessenkonflikte offen: keine. Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hartmann, S., Reimer, T. & Stachs, A. Adjuvante endokrine Therapie des Mammakarzinoms. Info Onkol. 19, 40–47 (2016). https://doi.org/10.1007/s15004-016-5413-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-016-5413-x

Search

Navigation